CD47 and cancer: TTI-621, a recombinant protein that blocks the CD47-SIRPα signaling in humans, is currently being studied in clinical trials including multiple solid tumors based on previous xenograft studies where it improved macrophage phagocytosis of cancer but not normal cells [183].